Pharvaris N.V.
- Open
- 34.58
- Day high
- 34.58
- Day low
- 33.33
- Prev close
- 34.58
- Volume
- 102K
- Mkt cap
- $2.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 8.8
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$8.0M over the last 3 months (0 open-market buys, 39 sales)
- 🏛Institutions accumulating (13F)
Pharvaris N.V. (PHVS) is a Healthcare company listed on NASDAQ. The stock is up 100% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 39 sales (SEC Form 4).
Pharvaris N.V. (PHVS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 5 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PHVS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.82 | $-0.70 | +14.8% | — | — |
| Nov 12, 2025 | $-0.78 | $-0.70 | +10.3% | — | — |
| Aug 12, 2025 | $-0.87 | $-0.94 | -8.0% | — | — |
| Mar 31, 2025 | — | $-0.93 | — | — | — |
| Aug 14, 2024 | $-0.57 | $-0.59 | -3.5% | — | — |
| Apr 3, 2024 | $-0.58 | $-0.82 | -41.4% | — | — |
| Nov 2, 2023 | $-0.67 | $-0.63 | +6.0% | — | — |
| Apr 5, 2023 | — | $-0.73 | — | — | — |
| Dec 8, 2022 | $-0.64 | $-0.25 | +60.9% | — | — |
| Jul 1, 2022 | — | $-0.39 | — | — | — |
| Jul 30, 2021 | $-0.51 | $-1.13 | -121.6% | — | — |
| May 26, 2021 | $-0.34 | $-0.66 | -94.1% | — | — |
PHVS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 14,700 | $2.59 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 3,400 | $35.09 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 11,600 | $34.45 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 15,000 | $2.59 |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrusdirector | Sell | 2,400 | $35.10 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 2,300 | $35.12 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Option | 900 | $8.05 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Option | 1,400 | $2.59 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 14,700 | $34.00 |
| Jun 23, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 300 | $34.00 |
| Jun 23, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 300 | $2.59 |
| Jun 17, 2026 | Modig Berndtdirector, officer: Chief Executive Officer | Sell | 100 | $31.46 |
| Jun 17, 2026 | Modig Berndtdirector, officer: Chief Executive Officer | Sell | 2,191 | $31.05 |
| Jun 16, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 117 | $32.20 |
| Jun 15, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 109 | $31.51 |
Source: PHVS SEC Form 4 filings, latest Jun 29, 2026. For informational purposes only — not investment advice.
See the full PHVS insider & 13F page →Pharvaris N.V. company profile
Overview
Pharvaris N.V. (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Leiden, the Netherlands. The company went public in February 2021 and operates across the Netherlands, Switzerland, and the United States. Pharvaris focuses exclusively on developing innovative therapies for hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling episodes. The company is currently advancing three drug candidates through various phases of clinical trials, with its lead compound having reached Phase II development.
Business
Pharvaris operates in the rare disease biotechnology sector, specifically targeting hereditary angioedema (HAE), a life-threatening genetic condition affecting approximately 1 in 50,000 people worldwide. HAE is caused by a deficiency or dysfunction of C1 esterase inhibitor, leading to uncontrolled production of bradykinin, a molecule that causes blood vessels to leak fluid into surrounding tissues. This results in unpredictable and potentially fatal swelling episodes, particularly dangerous when they occur in the throat or airways. The company's therapeutic approach centers on bradykinin B2-receptor antagonism, which blocks the pathway responsible for the swelling attacks. Pharvaris has developed three distinct drug candidates to address different treatment needs: 1. PHA121 represents the lead program, currently in Phase II clinical trials as an on-demand treatment for acute HAE attacks. This oral medication is designed to be taken when patients experience the onset of swelling symptoms. 2. PHVS416 is an on-demand, rapid-exposure soft capsule formulation also in Phase II trials, engineered for faster absorption and quicker onset of action during acute episodes. 3. PHVS719 is a prophylactic extended-release tablet in Phase I development, intended for daily use to prevent HAE attacks from occurring. All three compounds target the same biological mechanism but are formulated differently to serve the two primary treatment paradigms in HAE management: on-demand therapy for treating active attacks and prophylactic therapy for preventing future episodes.
Revenue model
As a clinical-stage biopharmaceutical company, Pharvaris currently generates no revenue and operates on a research and development model funded by investor capital. The company's future revenue will depend on successfully developing, obtaining regulatory approval for, and commercializing its HAE therapies. Upon successful commercialization, Pharvaris expects to generate revenue through direct product sales to patients, hospitals, and specialty pharmacies. The HAE market is characterized by high-priced specialty medications, with existing treatments often costing $300,000 to $500,000 annually per patient. The company's target customers include HAE patients, their treating physicians (typically allergists, immunologists, and hematologists), and specialty pharmacy networks that serve rare disease populations. Several factors could significantly impact Pharvaris's future profitability. Positive factors include the limited competition in HAE treatments, high unmet medical need driving premium pricing, potential for orphan drug designation providing market exclusivity, and the chronic nature of HAE requiring long-term treatment. The small, well-defined patient population also enables focused marketing efforts and strong physician relationships. Challenging factors include the high costs of rare disease drug development, regulatory risks inherent in clinical trials, competition from established HAE treatments and other companies developing bradykinin pathway inhibitors, and potential pricing pressure from payers despite the orphan indication. Manufacturing costs for small-molecule drugs and the need for specialized distribution networks also affect margins. Additionally, the company faces the typical biotech risks of clinical trial failures, regulatory delays, and the substantial capital requirements needed to reach profitability.
Competitive moat
Pharvaris operates in a competitive landscape with limited sustainable moats typical of clinical-stage biotechnology companies. The company's primary competitive advantages stem from its specialized focus on bradykinin B2-receptor antagonism and its comprehensive approach to HAE treatment with multiple formulations targeting different patient needs. The HAE market does offer some natural barriers to entry, including the small patient population requiring specialized expertise to conduct clinical trials, established relationships with key opinion leaders in the HAE community, and regulatory pathways that favor companies with deep disease area knowledge. Pharvaris has built expertise in HAE clinical development and has established relationships within the patient and physician communities. However, the company's moat is relatively weak compared to established biotechnology companies. Competitive threats include several well-funded companies developing HAE treatments, including large pharmaceutical companies with greater resources and established rare disease commercialization capabilities. Existing HAE treatments from companies like Takeda, CSL Behring, and BioCryst already serve the market, and these companies have strong physician relationships and distribution networks. The oral, small-molecule approach pursued by Pharvaris could provide advantages over injectable therapies in terms of patient convenience, but this differentiation may not be sufficient to establish a durable competitive position. Patent protection will be crucial but is time-limited, and the company lacks the manufacturing scale, brand recognition, and diversified product portfolio that provide stronger competitive moats. Success will largely depend on clinical trial outcomes and the ability to demonstrate superior efficacy, safety, or convenience compared to existing treatments.
Risks & safety
Pharvaris maintains a strong financial position with substantial cash reserves but faces typical biotech cash burn risks. • Liquidity position: Strong with $306.4 million in cash and short-term investments as of Q4 2024, providing significant runway for operations • Debt levels: Minimal debt with debt-to-equity ratio of only 0.32%, indicating very low leverage risk • Cash burn: Operating cash flow negative $131.1 million for full year 2024, suggesting approximately 2-3 years of runway at current burn rates • Current ratio: Excellent at 12.6x, indicating strong ability to meet short-term obligations • Solvency risk: Low in near term due to strong cash position, but will require additional funding or revenue generation within 2-3 years • Valuation considerations: As a pre-revenue biotech, traditional valuation metrics are not meaningful; company trades at 3.7x price-to-book ratio • Clinical risk: High binary risk profile typical of clinical-stage biotechnology companies, with success dependent on Phase II/III trial outcomes • Market opportunity: Focused on rare disease market with limited competition but also limited patient population
Recent development
Based on the financial data spanning 2022-2024, Pharvaris has been steadily advancing its clinical development programs while maintaining disciplined capital management. The company has demonstrated consistent progress in moving its lead compounds through clinical trials, with PHA121 and PHVS416 both reaching Phase II development and PHVS719 entering Phase I trials. The company's cash position has remained robust throughout this period, starting with $176.5 million at the end of 2022 and maintaining over $306 million by Q4 2024, despite significant research and development expenditures. This financial stability has enabled Pharvaris to pursue its comprehensive development strategy across multiple formulations simultaneously. Operating expenses have increased substantially as the company has advanced multiple clinical programs, with annual cash burn rising from approximately $73 million in 2022 to over $131 million in 2024. This increase reflects the natural progression from earlier-stage to more expensive late-stage clinical trials, particularly the costs associated with Phase II studies which typically require larger patient populations and more extensive monitoring. The company has maintained its focus exclusively on HAE treatments rather than expanding into other therapeutic areas, demonstrating strategic discipline in its core competency. This concentrated approach has allowed Pharvaris to build deep expertise in HAE clinical development and strengthen relationships within the patient and physician communities, positioning the company for potential commercial success upon regulatory approval.
PHVS company profile · for informational purposes only — not investment advice.
Track PHVS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free